Portal de Periódicos da CAPES

Analgesic Treatment in Acute Myocardial Infarction: A Double‐blind Comparison of Ketobemidone + the Spasmolytic A29 (Ketogan®) and Morphine

1988; Wiley; Volume: 223; Issue: 5 Linguagem: Inglês

10.1111/j.0954-6820.1988.tb15893.x

0001-6101

Tomas Wolff, SUNE LEWARD, Anders Hagman, Mats Andersson, LEONARD LARSSON, KJELL ELGEN,

Pharmacological Receptor Mechanisms and Effects

ABSTRACT. The analgesic effect of ketobemidone hydrochloride + the spasmolytic component A29 (Ketogan®) and morphine hydrochloride was compared double‐blindly in patients with suspect acute myocardial infarction. The test drugs were administered i.v. in an initial dose of 0.5 ml (2.5 mg Ketogan, 5 mg morphine) followed, if necessary, by additional injections of 0.25 ml. Altogether, 309 patients participated in the trial. The total comsumption of the test drugs showed that 5 mg Ketogan was equipotent with 10 mg of morphine. Treatment with Ketogan resulted in a significantly higher proportion of patients who were completely free of pain 15 and 30 min after the initial injection: 16% and 15% more, respectively, compared to morphine. Within 2 hours after the initial injection, approximately 15% of the patients in both treatment groups had reported nausea and about 7 % had vomited (patients who vomited or were nauseated before treatment were not included in this analysis). The frequency of other side‐effects was low, with no differences between the two treatment groups. Morphine caused a greater reduction of the systolic blood pressure than Ketogan. The effect of both drugs on pulse rate and respiration was the same.